Uses of Acipigrel

What is Acipigrel? Acipigrel is an antiplatelet drug with the main active ingredient being Clopidogrel (as Clopidogrel bisulphate) 75mg Clopidogrel is a prodrug and only the form metabolized by the CYP450 enzyme has inhibitory activity on platelet aggregation. Platelet aggregation is an important step in clot formation, therefore, by virtue of this activity, clopidogrel has the potential to prevent vascular occlusion due to thrombus formation.
Platelets that have been exposed to clopidogrel will experience an inhibitory effect on drug adhesion for the rest of their life because the drug's binding to the ADP receptor is irreversible. When the new platelets are fully produced, the adhesion effect of the platelets will return to normal.

Acipigrel is indicated for primary prevention of thrombus formation to reduce complications such as:
Myocardial infarction Cerebrovascular accident Peripheral artery disease Secondary prevention and control of progression in Patients with stroke, myocardial infarction with atherosclerosis or those who already have peripheral artery disease. People who have just experienced an acute coronary syndrome without ST-segment elevation. Acipigrel should not be used in the following cases:
People who are hypersensitive to Clopidogrel or any of the ingredients in Acipigrel. Patients with severe liver failure Patients with gastrointestinal bleeding, retinal bleeding or intracranial hemorrhage.

3.1. How to use Acipigrel is taken orally. Patients should take the entire tablet of Acipigrel 75mg, do not chew, break, crush because it can reduce the effectiveness of the drug. Acipigrel can be taken with or without food.
3.2. Dosage Prophylaxis to prevent thromboembolic complications such as cerebrovascular accident, myocardial infarction or peripheral artery disease: 75 mg/time x 1 time/day People with a history of atherosclerosis: 75 mg/day times x 1 time/day Acute coronary syndrome without ST-segment elevation including myocardial infarction without ST-segment elevation and unstable angina: Initial dose with 300 mg as a single dose, then maintenance dose of 75 mg per day.

Before prescribing Acipigrel, doctors always weigh the benefits and effectiveness against the risk of side effects. In general, clopidogrel is generally well tolerated, however, some patients may still experience unwanted effects during treatment.
Common: gastrointestinal disorders such as abdominal pain, diarrhea, dyspepsia, or skin allergies such as itching, erythema Uncommon: nosebleeds, gastrointestinal bleeding, chest tightness Rare: peptic ulcer, severe neutropenia, agranulocytosis, acute liver failure, hepatitis, purpura, thrombocytopenia, aplastic anemia, loss of taste. If you experience unusual symptoms during treatment with Acipigrel, you should stop taking the drug and notify your doctor for instructions on how to handle it.

Acipigrel may interact if used concomitantly with the following drugs and substances:
Acetysalicylic acid (ASA): Clopidogrel used concomitantly with Acetylsalicylic Acid may increase the risk of bleeding. Drugs that inhibit CYP2C19 enzyme activity such as fluoxetin, fluconazole, omeprazol, esomeprazol, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine: decrease plasma concentrations of the active metabolite clopidogrel in heparin: although concomitant use of clopidogrel and heparin is common does not affect the antiplatelet ability of clopidogrel or the blood clotting process of the body. However, the combined use of these two drugs may increase the risk of bleeding. Non-steroidal anti-inflammatory drugs (NSAIDs): Concomitant use with clopidogrel increases the risk of gastrointestinal bleeding. Therefore, caution should be exercised when using non-steroidal anti-inflammatory drugs in humans being treated with clopidogrel.

During the use of Acipigrel, patients should note:
Be careful in people with a history of bleeding such as retinal hemorrhage, gastrointestinal bleeding, intracranial hemorrhage, peptic ulcer. Caution should be exercised when using Acipigrel in patients with hepatic, renal or metabolic impairment. Caution should be exercised in patients with bleeding due to trauma, surgery or other conditions. Thrombocytopenic purpura with symptoms of fever and hemolytic anemia may occur, but with a very rare frequency. Patients who have recently undergone surgery, procedures with bleeding or who are in the first weeks of treatment with Acipigrel should be closely monitored for signs of occult bleeding. Patients who are indicated for surgery or procedures, need to stop taking Acipigrel before 5-7 days. Acipigrel does not affect the ability to use machines or drive a vehicle. There are no adequate studies on the safety of clopidogrel in pregnant women. Therefore, it is not recommended to prescribe Acipigrel to this patient unless absolutely necessary. Lactation: The excretion of Clopidogrel in Acipigrel into breast milk has not been established. Therefore, caution should be exercised when Acipigrel is used in women who are breastfeeding.

Symptoms of Acipigrel overdose: visceral bleeding, intracranial hemorrhage, orbital hemorrhage, gastrointestinal bleeding, nosebleed, subcutaneous bleeding or prolongation of bleeding time. Symptoms of acute toxicity such as vomiting, shortness of breath, fatigue. If you experience the above symptoms after taking an overdose of Acipigrel, the patient should stop the drug immediately and notify the treating doctor or go to a medical facility for timely treatment.
Currently there is no specific antidote for Acipigrel overdose. Emergency treatment of prolonged bleeding, internal bleeding is the most important thing. Platelet transfusion therapy may be used to limit the effects of Acipigrel.
Above is all information about Acipigrel's uses, dosage and important notes when using. Acipigrel is a prescription drug, patients only use it according to the instructions and instructions of the doctor to ensure safety and effective treatment.